Can hormone therapy, zearalenone exposure, slower estrogen metabolism, and gut dysbiosis create mixed estrogen signaling?

In postmenopausal women, the systemic and tissue-specific actions of estrogen are governed by a complex interplay of exogenous therapy, environmental exposures, hepatic metabolism, and gut microbiome activity.

Mechanistic pathways of mixed signaling

• Competitive Receptor Binding: Exogenous 17β-estradiol increases systemic load, while the mycotoxin zearalenone acts as a selective estrogen receptor modulator (SERM). Zearalenone binds ERα (IC50 ~240 nM) and ERβ (IC50 ~166 nM) and metabolizes into alpha-zearalenol (α-ZEL), which exhibits 3-4 fold higher estrogenic potency.
• Impaired Clearance and Reabsorption: Genetic variants slowing clearance (such as COMT Val158Met and UGT1A1*28) lead to local accumulation of reactive 4-hydroxyestradiol via CYP1B1. Simultaneously, gut dysbiosis elevates microbial beta-glucuronidase, deconjugating estrogen metabolites and promoting systemic reabsorption back into circulation.

Tissue-specific clinical effects

• Proliferative Stimulation: In breast and uterine tissues, the combination of high systemic estrogens, potent α-ZEL, and CYP1B1/COMT imbalances drives proliferative pathologies, clinically manifesting as uterine fibroids and fibrocystic breast changes (nodularity and tenderness).
• Localized Urogenital Deficiency: In contrast, competitive receptor occupancy by environmental estrogens in urogenital tissues can mimic certain SERMs, failing to provide adequate local estrogenic stimulation and potentially contributing to urogenital atrophy and vaginal dryness.

Bottom line

• The interaction of exogenous hormones, zearalenone exposure, impaired hepatic detoxification, and estrobolome activity can create a discordant estrogenic environment characterized by pathological breast and uterine proliferation alongside localized urogenital deficiency.